Thermo Fisher’s $912.5 Million Acquisition Expands Clinical Research with CorEvitas Purchase

Thermo Fisher Scientific has acquired CorEvitas for $912.5 million from Audax Private Equityin to enhance its clinical research sector. Based out of Waltham, Massachusetts, CorEvitas provides real-world evidence services to this established biotechnology company, managing patient health outcomes data for pharmaceutical and biotechnology companies. This acquisition has provided Thermo Fisher access to extensive real-world data from 12 different registries, integrating over 300,000 patient-years of follow-ups and more than 1,000 peer-reviewed studies into their offerings. CEO of Thermo Fisher, Marc Casper, highlighted the acquisition’s strategic fit, particularly how it will improve their PPD clinical research business and responsiveness to the strong market demand for real-world evidence, facilitating more efficient drug development. This strategic acquisition positions Thermo Fisher to better serve the evolving needs of the life sciences industry.

To read more, click here.

[Source: The Middle Market, Mergers & Acquisitions. May 6, 2024.]